Top 10 FDA Recalls Physicians Should Know - Top-Institutions - MDSpire

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

  • By

  • Conexiant News Staff

  • June 18, 2026

  • 5 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Regulatory Science
    • Pharmacoepidemiology

  • #2

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Pharmacoepidemiology
    • Public Health

  • #3

    University of North Carolina at Chapel Hill
    University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

    Key Differentiators

    • Public Health
    • Epidemiology

  • #4

    Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical Center

    Boston, Massachusetts

    Key Differentiators

    • Emergency Medicine
    • Public Health

  • #5

    American College of Obstetricians and Gynecologists
    American College of Obstetricians and Gynecologists

    Washington, D.C.

    Key Differentiators

    • Obstetrics
    • Gynecology

Original Source(s)

Top 10 FDA Recalls Physicians Should Know

  • by Conexiant News Staff

  • June 18, 2026

Related Content

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Sugar-Sweetened Beverages May Raise Risk of  Hepatic Cancer Subtypes

In a pooled analysis of more than 1.5 million patients, sugar-sweetened beverages were associated with higher risks of HCC and ICC, while artificially-sweetened beverages showed no independent association with hepatic cancer.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.